Loading...
Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has...
Na minha lista:
| Udgivet i: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6452813/ https://ncbi.nlm.nih.gov/pubmed/31040693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S141040 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|